Global Assisted Reproductive Technology Market is valued at USD 32.37 Billion in 2022 and is expected to reach USD 63.88 Billion by 2029 with a CAGR of 10.2% over the forecast period.
Global Assisted Reproductive Technology Market Global Size, Trends, Competitive, Historical & Forecast Analysis to 2022-2028, Increasing number of reproductive problems, rising awareness about infertility treatments are driving the growth of the Global Assisted Reproductive Technology Market.
ART (assisted reproductive technology), primarily an uncontrolled multi-billion dollar industry is the only type of medical treatment that has the ""ultimate goal"" of creating another person. Basic ART (assisted reproductive technology) involves dietary changes, lifestyle changes, and medication or hormone therapy, and approximately 85% of infertility cases are treated with these measures. Additionally, more sophisticated and invasive interventions include intrauterine insemination (IUI) and in vitro fertilization (IVF). Intrauterine insemination (IUI) is a relatively simple nonsurgical procedure in which sperm produced by a partner or donor is inserted into a woman's uterus during her ovulatory phase and brought closer to the ovum. In vitro fertilization (IVF) is a more complicated procedure in which the ovum is removed from a woman's body by laparoscopy, fertilized by her spouse's or donor's semen, incubated in a laboratory dish until the embryo develops, and then transferred to the woman's uterus. Some couples may also need a gamete intrafallopian transfer or zygote intrafallopian transfer.
All but the most basic ART require treatment by a doctor, usually a reproductive endocrinologist or urologist. Additionally, intrauterine insemination (IUI) and in vitro fertilization (IVF) can also be used for surrogate pregnancies. The surrogate is a third party who conceives the baby for a full term, realizing that she will give the baby to the desired parent. In pregnancy surrogacy, the woman is conceived with the fertilized egg of the expected couple (using either the couple's gametes or donor gametes); thus, the surrogate does not have a genetic relationship with the baby. In partial surrogacy, the woman is implanted with the intended father's sperm (or donor's sperm) for the purpose of fertilizing one of the surrogate's own eggs; in this case, the surrogate is genetically related to the baby.
The Covid-19 has affected millions of people worldwide, resulting in high mortality rates. Local disease has had a negative impact on the auxiliary reproductive technology market due to mobility limitations and safety concerns during the process. Many organizations have undertaken initiatives to maintain reproductive health standards. The decrease in the number of ART procedures at the beginning of Covid-19 has affected the market growth.
The Global assisted reproductive technology market is segmented on basis of technology, product, end-user, and region & country level. On the basis of product, the assisted reproductive technology market is classified into instrument, accessory & disposable, and reagents & media. On the basis of technology, the market is classified into, in vitro-fertilization, artificial insemination, and others. On the basis of end-use, the assisted reproductive technology market is classified into fertility clinics, hospitals, surgical centers, and clinical research institute.
The regions covered in this global assisted reproductive technology market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of global assisted reproductive technology is subdivided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Some of the key players for the assisted reproductive technology market are:
On August 24th, 2020; Silverfleet Capital, a Pan-European private equity firm, entered into a binding agreement with CARE Fertility Holdings Limited (CARE or Company) on April 25, 2019 to acquire a majority stake. Headquartered in Nottingham, England, the company is the UK's leading breeding service provider with a strong scientific and clinical backbone. The terms of the transaction were not disclosed.
On September 16th, 2019; Monash, a Richmond-based Victoria-based healthcare facility, bought some property, liability, and fertility solutions contracts, with potential additional earnings payments for a period of four years running through June 30, 2023. Monash's operations in Queensland will be expanded with the addition of two clinics, one in Sunshine Coast and one in Bundaberg.
On August 6th, 2018; GI Partners completed the previously announced acquisition and merger of California Cryobank (CCB), the world's leading donor sperm and egg bank and cord blood registry (CBR), the world's largest stem cell collection and storage company. California CryoBank Life Sciences is a leading company in the stem cell storage and reproductive tissue services market.
The growth of the global assisted reproductive technology market is largely driven by rising number of cases of infertility rates; increased funding from private and government agencies for infertility services; rising awareness about infertility treatment and surrogacy; and an increase in technology in auxiliary reproductive technology. According to the World Health Organization (WHO); by 2020, an estimated 186 million individuals and 48 million couples have been diagnosed with infertility. According to the Centers for Disease Control and Prevention (CDC), approximately six percent to 12 percent of U.S. women with PCOS were also diagnosed with infertility. The Brandessence report estimates that one in six American couples experiences infertility at some point and about 14 percent of married couples who have not been surgically sterilized experience infertility in any given year. More precisely, nine out of every 100 women worldwide between the ages of 20 and 44 cannot conceive. As Dave Shed states, “Because disability only has a neutral or negative effect on fertility, people with disabilities are just as likely as or more likely to experience infertility than people with disabilities. Thus, it is expected that at least fourteen percent of heterosexual couples trying to conceive, with at least one partner having a disability, are infertile in any year, and at least one-sixth of such couples will experience infertility at some point in their relationship. An estimated 7.3 million couples in the United States are currently experiencing infertility.
By 2025, that number is projected to rise to an estimated 7.7 million. For instance; in February 2021, TMRW Life Sciences, a life science technology company providing a platform for monitoring and tracking, announced the launch of the world's first automated cryo sampling management solution for eggs and embryos used in In vitro fertilization (IVF) process. Thus, advances in technology, software, and imaging systems have been used to monitor fetal growth on monitors. Furthermore, in 2018, LUMSA University in Italy announced the WoMoGeS (Women’s Movement and Pregnancy Surrogacy) project, which aims to raise awareness about pregnancy surrogacy among vulnerable women in developing countries. Furthermore, the presence of emerging key players in auxiliary reproductive technology and the increase in disposable income drive the growth of the market.
However, the high value associated with the treatment and socio-ethical stigma regarding the procedures may limit the adoption of assisted reproductive technology in the global market. According to Brandessence, most women in emerging countries cannot afford infertility services due to their high costs.
In spite of that, a rise in demand for in-vitro fertilization for effective treatment, and high success rate acts may offer more growth opportunities for the further growth of the global assisted reproductive technology market.
Europe is expected to capture the major share of the assisted reproductive technology market owing to the increasing prevalence of infertility with the high demand for ART procedures in this region. Spain, Denmark, the United Kingdom, Germany, and France are the most active breeding nations in Europe, and market growth is expected to continue. In Spain, for example, 140,909 ART treatment cycles are performed annually, according to the European Society of Human Reproduction and Embryology.
North America is the second dominant region in the assisted reproductive technology market owing to the increasing adoption of reproductive services in patients in the U.S.. In addition, increasing disposable income and the high utilization of technologically advanced services are driving the adoption of these services in the region during the forecast period.
|Historical data||2016 - 2021|
|Forecast Period||2022 - 2029|
|Market Size in 2022:||USD 32.37 Billion|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2029:||USD 63.88 Billion|
|Tables, Charts & Figures:||175|
|Assisted Reproductive Technology Manufacturers||Cook Medical Inc., Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.), Genea Biomedx, Merck KGaA (EMD Serono, Inc.), Millendo Therapeutics, Inc., Oxford Gene Technology, Progyny Inc., The Cooper Companies, Inc. (CooperSurgical, Inc.), Thermo Fisher Scientific, Inc., Vitrolife AB, others|
|Segments Covered||By Product, By Technology, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
On Special Requirement Assisted Reproductive Technology Market Report is also available for below Regions and Country:
Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®